PERSONAL SUMMARY:
Dr. Mou joined Liu, Shen & Associates in 2010. He specializes in patent
drafting, prosecution, re-examination, invalidation, administrative litigation,
legal opinion, client counseling and due diligence with a focus on the field of
pharmaceutical science, crop science, chemistry, material, food, cosmetics, biology
and so on.
Dr. Mou is qualified as a patent attorney in 2012, and qualified as an
attorney at law in 2015. He has participated in several patent lawsuits
including patent infringement and patent invalidation. He has also participated
in patent stability analysis, FTO, patent searching and infringement analysis,
as well as trade secret counseling in the firm.
Dr. Mou received his bachelor’s degree and doctorial degree in
Medicinal Chemistry fromPekingUniversityin 2004
and 2010 respectively. Before joining this firm, Dr. Mou has completed a whole
year internship at the HIV department of GSK in NC,USA. He also had a four months’
secondment at Bayer China Limited in 2015, to assist the IPR department with
the IP affairs.
Dr. Mou joined a course at China University of Political science and
Law for master’s degree in civil and commercial law and intellectual property law
in 2016-2017, and received his Master of Laws (LLM) degree from The John
Marshall Law School (JMLS) in Chicago, IL, USA, with a major on Intellectual
Property Law, in 2017, with Honors.
HIGHLIGHTS:
Dr. Mou has a
good scientific background in the pharmaceutical industry, and has a good
understanding of the Patent Portfolio of the pharmaceutical companies including
R&D, patent application and patent enforcement.
Presentations
given by Dr. Mou include:
- Legal concept and its purposeful explanation
- Amendments to claims in an invalidation procedure
- Strategy of establishing the inventiveness for inhibitors
with a different target
- Overview of trade secret
- Trade secret -- cases from the Supreme
Court
- Practice and tips in pharmaceutical patent drafting
Paper published
by Dr. Mou on the website of Liu & Shen includes:
- Overview of trade secret
- Amending a Markush claim in an invalidation
procedure becomes more difficult